Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
NEJM Perspective Details a Team Effort to Counter an Online Disinformation Campaign
The ELEGANCE Registry: Working to Achieve Equity in Clinical Research Design | NEJM Catalyst
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation | NEJM
Alex Evans - Senior Software Engineer - VIDA | LinkedIn
NEJM paper retracted for “inaccuracies in the analytic database and data analyses” – Retraction Watch
Alex Stern | NEJM Wade (2022) | Available for Sale | Artsy
Alex Stern, NEJM Flower, 2022 | Trotter&Sholer
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM
The Role of PIEZO2 in Human Mechanosensation | NEJM
Memoir of the Late Alexander C. Becker, M.D. | NEJM
The Late Dr Alexander Read, of New Bedford | NEJM
NEJM 30 Seconds | Artwork | eazel
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM
alex meraz — Blog — NephJC
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation | NEJM
Alex Stern | NEJM Dive (2023) | Available for Sale | Artsy
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer | NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation | NEJM
إبراهيم الحربي Ibrahim Alharbi on X: "Perioperative Management of Anticoagulant and Antiplatelet Therapy. Source : NEJM May 2023 https://t.co/5wdDGYjnms https://t.co/ywiJfrBomg" / X
NEJM Knowledge+ Welcomes Dr. Alex Djuricich as NEJM Group Education Editor - NEJM Knowledge+
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Oxygen in the Treatment of Coronary Occlusion in the Home | NEJM
Alex Stern | NEJM Jesus (2023) | Available for Sale | Artsy
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer | NEJM
